शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
AMRUTANJANNSEAmrutanjan Health Care Limited· Pharmaceuticals & BiotechnologyHighPositive
Announced Mon, 10 Nov, 2025 · 16:38 IST

Amrutanjan Health Care Q2 FY26 results: PAT up 36% in H1, Re.1 interim dividend

AMRUTANJAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.7%Reaction day
₹701.90
prior close
₹711.00
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+4.0% vs market
Pharmaceuticals peers, median of 157sector-0.2%+4.0% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.7
10m
+2.8
15m
+3.5
30m
+3.1
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.7-0.3+4.0-0.2+4.0
Next day
+1.3+0.7+0.7+0.5+0.8
2d
+1.3+0.6+0.7+0.6+0.8
3d
+3.0+0.5+2.5+0.3+2.7
4d
+1.2+1.1+0.1+0.2+1.0
5d
+0.3+0.3+0.0-0.6+0.9
1w
-0.3-0.2-0.0-1.1+0.8
15d
-4.1-2.2-1.9-2.0-2.2
1m
-7.5-4.9-2.6-2.9-4.7
2m
-13.1-7.5-5.6-5.8-7.2
3m
-7.5-4.8-2.7-6.4-1.1
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Amrutanjan Health Care Q2 FY26: revenue Rs 117.70 cr, up 7% YoY; PAT Rs 13.96 cr, up 18% YoY. H1 revenue Rs 211.75 cr vs Rs 193.65 cr; H1 PAT Rs 22.27 cr vs Rs 16.41 cr, up about 36% YoY. Quarter EPS Rs 4.83 vs Rs 4.08. Board declared first interim dividend of Re.1 per share for FY26. OTC Products led growth; Beverages losses narrowed. Auditor issued an unmodified limited review report.

Likely market impact

H1 PAT growth of 36% and an interim dividend of Re.1 per share signal strong performance and steady shareholder returns.